ArticleJournal of neurology2025
Impact of disease activity on quality of life and EQ-5D-3L score in myasthenia gravis: results from the Swedish MG registry.
Article in Journal of neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionMyasthenia gravis (MG) is an autoimmune disease causing motor fatiguability. The impact of MG on quality of life (QoL) is incompletely studied. Here, we explore the impact of disease activity on QoL.
methodsUsing the Swedish nationwide MG registry, 150 MG cases with concomitant EQ-5D-3L and MG-ADL, QMG and/or MG-QoL-15 scores were identified. An EQ-5D score was derived from EQ-5D-3L using the UK time trade-off tariff and compared to a Swedish reference population. Longitudinal analysis assessing the impact of change in MG-ADL on QoL was performed on data from the randomized-controlled RINOMAX trial.
resultsEQ-5D score was negatively correlated with MG-ADL, QMG and MG-QoL-15 (R = - 0.48, - 0.33, and - 0.66, respectively; p < 0.01). The usual activities dimension deviated most from reference population, although all dimensions were significantly impacted. Lower EQ-5D score was observed already at low-to-moderate disease activity, MG-ADL 3-5 points, compared to reference (0.71 [SD 0.23] vs. 0.81 [SD 0.04]; p = 0.01), and was further decreased with higher disease activity. Longitudinal analyses revealed a significant decrease of EQ-5D score per point increase in MG-ADL (β -0.050 [95%CI -0.077, -0.023]; p < 0.001). Most impact on EQ-5D score was observed by limb and respiratory items (limb β - 0.17 [95%CI - 0.26, - 0.071]; p = 0.001, respiratory β - 0.21 [95%CI - 0.39, - 0.031]; p = 0.022), while bulbar symptoms showed no effect on EQ-5D score.
conclusionsWe observed a considerably decreased EQ-5D score already at low disease activity in MG patients, worsening with increasing disease activity. This indicates an unmet medical need that warrants improved treatment and care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.